Search Results | Cancer Research | American Association for Cancer Research

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Abstract 993: GDF15 is a candidate circulating biomarker of eribulin response in breast cancer

Chiara Bellio, Marta Emperador, Laia Garrigós, Esther Zamora, Cristina Saura, Bruce A. Littlefield, Josep Villanueva

Cancer Res (2021) 81 (13_Supplement): 993.

DOI: https://doi.org/10.1158/1538-7445.AM2021-993

Published: 01 July 2021

View article

Journal Articles

Abstract 1399: Tumor-specific molecular changes in luminal B breast cancer patient-derived xenografts (PDXs) with acquired resistance to endocrine treatment

Marc Hillairet De Boisferon, Ismahène Benzaid, Elodie Marie Dit Chatel, Nicolas Hoffmann, Bruce A. Littlefield

Cancer Res (2021) 81 (13_Supplement): 1399.

DOI: https://doi.org/10.1158/1538-7445.AM2021-1399

Published: 01 July 2021

View article

Journal Articles

Abstract 5522: Evaluation of eribulin-induced alterations of the intact immune cell landscape in spleens and tumors from tumor-bearing immunocompetent mice

Haochen Wu, Keyi Zhu, Xiaolong Tu, Diana Albu, Mary Woodall-Jappe, Bruce A. Littlefield

Cancer Res (2020) 80 (16_Supplement): 5522.

DOI: https://doi.org/10.1158/1538-7445.AM2020-5522

Published: 15 August 2020

View article

Journal Articles

Abstract 4280: Potential molecular biomarkers of response to eribulin in patients with leiomyosarcoma

Agnieszka Wozniak, Bram Boecks, Elodie Modave, Amy Weaver, Diether Lambrechts, Bruce A. Littlefield, Patrick Schöffski

Cancer Res (2020) 80 (16_Supplement): 4280.

DOI: https://doi.org/10.1158/1538-7445.AM2020-4280

Published: 15 August 2020

View article

Journal Articles

Abstract 1924: Genetic analysis of responses to eribulin versus vinorelbine and paclitaxel in 100 cancer cell lines from the cancer cell line Encyclopedia (CCLE)

Pallavi Sachdev, Roy Ronen, Janusz Dutkowski, Bruce A. Littlefield

Cancer Res (2020) 80 (16_Supplement): 1924.

DOI: https://doi.org/10.1158/1538-7445.AM2020-1924

Published: 15 August 2020

View article

Journal Articles

Abstract 4719: Synergistic anticancer activity of triple combinations of eribulin, palbociclib and fulvestrant in hormone dependent patient-derived xenograft (PDX) models of human breast cancer

Marc Hillairet de Boisferon, Elodie Marie Dit Chatel, Kenichi Nomoto, Bruce A. Littlefield

Cancer Res (2019) 79 (13_Supplement): 4719.

DOI: https://doi.org/10.1158/1538-7445.AM2019-4719

Published: 01 July 2019

View article

Journal Articles

Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery

Cancer Res (2018) 78 (3): 817–829.

DOI: https://doi.org/10.1158/0008-5472.CAN-17-1467

Published: 31 January 2018

View article

Includes: Supplementary data

Journal Articles

Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity

Krystyna M. Wozniak, James J. Vornov, Ying Wu, Kenichi Nomoto, Bruce A. Littlefield, Christopher DesJardins, Yanke Yu, George Lai, Larisa Reyderman, Nancy Wong, Barbara S. Slusher

Cancer Res (2016) 76 (11): 3332–3339.

DOI: https://doi.org/10.1158/0008-5472.CAN-15-2525

Published: 31 May 2016

View article

Journal Articles

Abstract 4503: Pharmacokinetics and pharmacodynamic analysis of eribulin mesylate and paclitaxel in mouse

Krystyna Wozniak, Ying Wu, Bruce A. Littlefield, Kenichi Nomoto, Christopher DesJardins, Yanke Yu, George Lai, Larisa Reyderman, Barbara S. Slusher

Cancer Res (2015) 75 (15_Supplement): 4503.

DOI: https://doi.org/10.1158/1538-7445.AM2015-4503

Published: 01 August 2015

View article

Journal Articles

Abstract 1698: Identification of drugs with eribulin combinatorial activity that kill both eribulin-sensitive and eribulin-insensitive tumor cells

Toshimitsu Uenaka, Richard Rickles, Yasuhiro Funahashi, Ping Zhu, Jill M. Grenier, Janine Steiger, Nanding Zhao, Bruce A. Littlefield, Junji Matsui, Kenichi Nomoto

Cancer Res (2014) 74 (19_Supplement): 1698.

DOI: https://doi.org/10.1158/1538-7445.AM2014-1698

Published: 01 October 2014

View article

Journal Articles

Abstract 4653: Pharmacokinetics and biodistribution of eribulin mesylate, paclitaxel, and ixabepilone in mouse

Krystyna Wozniak, Ying Wu, Kenichi Nomoto, Bruce A. Littlefield, Christopher DesJardins, Edgar Schuck, Phil Saxton, Nancy Wong, Barbara S. Slusher

Cancer Res (2014) 74 (19_Supplement): 4653.

DOI: https://doi.org/10.1158/1538-7445.AM2014-4653

Published: 01 October 2014

View article

Journal Articles

Abstract 5503: Microtubule-targeting agents induce differential myelinated axon degeneration in a mouse model of peripheral neuropathy

Brett M. Cook, Sarah J. Benbow, Krystyna M. Wozniak, Barbara S. Slusher, Bruce A. Littlefield, Leslie Wilson, Stuart C. Feinstein, Mary Ann Jordan

Cancer Res (2014) 74 (19_Supplement): 5503.

DOI: https://doi.org/10.1158/1538-7445.AM2014-5503

Published: 01 October 2014

View article

Journal Articles

Abstract 5464: Distinct effects of eribulin on axonal microtubule composition and modifications relative to paclitaxel, vincristine and ixabepilone in preclinical models: correlations with lower levels of eribulin-induced peripheral neuropathy

Sarah J. Benbow, Brett M. Cook, Krystyna M. Wozniak, Barbara S. Slusher, Bruce A. Littlefield, Leslie Wilson, Stuart C. Feinstein, Mary A. Jordan

Cancer Res (2014) 74 (19_Supplement): 5464.

DOI: https://doi.org/10.1158/1538-7445.AM2014-5464

Published: 01 October 2014

View article

Journal Articles

Abstract 1227: Macrophage depletion enhances the anticancer efficacy of eribulin mesylate in mice bearing syngeneic tumors.

Diana I. Albu, Bruce A. Littlefield, Mary Woodall-Jappe

Cancer Res (2013) 73 (8_Supplement): 1227.

DOI: https://doi.org/10.1158/1538-7445.AM2013-1227

Published: 15 April 2013

View article

Journal Articles

Abstract 4493: Eribulin recognizes the nucleotide states of soluble tubulin and binds with high-affinity on a site distinct from known tubulin inhibitors.

Kishan Lal Agarwala, Kenji Kubara, Koji Sagane, Boris M. Seletsky, Bruce A. Littlefield

Cancer Res (2013) 73 (8_Supplement): 4493.

DOI: https://doi.org/10.1158/1538-7445.AM2013-4493

Published: 15 April 2013

View article

Journal Articles

Abstract 899: Characterization and establishment of a drug-resistant human lung cancer model.

Kuan-Chun Huang, Judith Oestreicher, Natalie Twine, Winnie Lee, Xingfeng Bao, Sergei Agoulnik, Bruce A. Littlefield, Mary Woodall-Jappe, Kenichi Nomoto

Cancer Res (2013) 73 (8_Supplement): 899.

DOI: https://doi.org/10.1158/1538-7445.AM2013-899

Published: 15 April 2013

View article

Journal Articles

Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice

Krystyna M. Wozniak, Kenichi Nomoto, Rena G. Lapidus, Ying Wu, Valentina Carozzi, Guido Cavaletti, Kazuhiro Hayakawa, Satoru Hosokawa, Murray J. Towle, Bruce A. Littlefield, Barbara S. Slusher

Cancer Res (2011) 71 (11): 3952–3962.

DOI: https://doi.org/10.1158/0008-5472.CAN-10-4184

Published: 31 May 2011

View article

Includes: Supplementary data

Journal Articles

Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions

Murray J. Towle, Kathleen A. Salvato, Bruce F. Wels, Kimberley K. Aalfs, Wanjun Zheng, Boris M. Seletsky, Xiaojie Zhu, Bryan M. Lewis, Yoshito Kishi, Melvin J. Yu, Bruce A. Littlefield

Cancer Res (2011) 71 (2): 496–505.

DOI: https://doi.org/10.1158/0008-5472.CAN-10-1874

Published: 13 January 2011

View article

Includes: Supplementary data

Journal Articles

Abstract LB-324: A toll-like receptor 4 agonist enhances the efficacy of trastuzumab therapy and promotes adaptive immunity and long-term protection against a human ErbB-2 (HER2)-transfected syngeneic tumor in a human HER2 transgenic mouse model

Shangzi Wang, Wei Xu, Yong Tang, Rishi Surana, Catherine Bingham, Igor A. Astsaturov, Kenneth McCarthy, R. Katherine Alpaugh, Bruce A. Littlefield, Lynn D. Hawkins, Sally T. Ishizaka, Louis M. Weiner

Cancer Res (2010) 70 (8_Supplement): LB-324.

DOI: https://doi.org/10.1158/1538-7445.AM10-LB-324

Published: 15 April 2010

View article

Journal Articles

Abstract 4438: Comparison of neuropathy-inducing effects of eribulin versus paclitaxel in mice

Krystyna M. Wozniak, Rena G. Lapidus, Ying Wu, Valentina Carozzi, Guido Cavalleti, Kazuhiro Hayakawa, Satoru Hosokawa, Murray J. Towle, Bruce A. Littlefield, Kenichi Nomoto, Barbara S. Slusher

Cancer Res (2010) 70 (8_Supplement): 4438.

DOI: https://doi.org/10.1158/1538-7445.AM10-4438

Published: 15 April 2010

View article

NARROW

Abstract 993: GDF15 is a candidate circulating biomarker of eribulin response in breast cancer

Abstract 1399: Tumor-specific molecular changes in luminal B breast cancer patient-derived xenografts (PDXs) with acquired resistance to endocrine treatment

Abstract 5522: Evaluation of eribulin-induced alterations of the intact immune cell landscape in spleens and tumors from tumor-bearing immunocompetent mice

Abstract 4280: Potential molecular biomarkers of response to eribulin in patients with leiomyosarcoma

Abstract 1924: Genetic analysis of responses to eribulin versus vinorelbine and paclitaxel in 100 cancer cell lines from the cancer cell line Encyclopedia (CCLE)

Abstract 4719: Synergistic anticancer activity of triple combinations of eribulin, palbociclib and fulvestrant in hormone dependent patient-derived xenograft (PDX) models of human breast cancer

Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery

Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity

Abstract 4503: Pharmacokinetics and pharmacodynamic analysis of eribulin mesylate and paclitaxel in mouse

Abstract 1698: Identification of drugs with eribulin combinatorial activity that kill both eribulin-sensitive and eribulin-insensitive tumor cells

Abstract 4653: Pharmacokinetics and biodistribution of eribulin mesylate, paclitaxel, and ixabepilone in mouse

Abstract 5503: Microtubule-targeting agents induce differential myelinated axon degeneration in a mouse model of peripheral neuropathy

Abstract 5464: Distinct effects of eribulin on axonal microtubule composition and modifications relative to paclitaxel, vincristine and ixabepilone in preclinical models: correlations with lower levels of eribulin-induced peripheral neuropathy

Abstract 1227: Macrophage depletion enhances the anticancer efficacy of eribulin mesylate in mice bearing syngeneic tumors.

Abstract 4493: Eribulin recognizes the nucleotide states of soluble tubulin and binds with high-affinity on a site distinct from known tubulin inhibitors.

Abstract 899: Characterization and establishment of a drug-resistant human lung cancer model.

Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice

Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions

Abstract LB-324: A toll-like receptor 4 agonist enhances the efficacy of trastuzumab therapy and promotes adaptive immunity and long-term protection against a human ErbB-2 (HER2)-transfected syngeneic tumor in a human HER2 transgenic mouse model

Abstract 4438: Comparison of neuropathy-inducing effects of eribulin versus paclitaxel in mice

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only